DaVita Receivables 2010-2024 | DVA

DaVita receivables from 2010 to 2024. Receivables can be defined as the total amount of collectibles for a company
  • DaVita receivables for the quarter ending June 30, 2024 were $2.733B, a 15.47% increase year-over-year.
  • DaVita receivables for 2023 were $2.416B, a 5.28% decline from 2022.
  • DaVita receivables for 2022 were $2.551B, a 5.81% increase from 2021.
  • DaVita receivables for 2021 were $2.411B, a 1.16% decline from 2020.
DaVita Annual Receivables
(Millions of US $)
2023 $2,416
2022 $2,551
2021 $2,411
2020 $2,439
2019 $2,305
2018 $2,397
2017 $2,163
2016 $1,792
2015 $2,220
2014 $2,011
2013 $1,845
2012 $1,742
2011 $1,477
2010 $1,394
2009 $1,369
DaVita Quarterly Receivables
(Millions of US $)
2024-06-30 $2,733
2024-03-31 $2,991
2023-12-31 $2,416
2023-09-30 $2,378
2023-06-30 $2,367
2023-03-31 $2,382
2022-12-31 $2,551
2022-09-30 $2,493
2022-06-30 $2,635
2022-03-31 $2,502
2021-12-31 $2,411
2021-09-30 $2,491
2021-06-30 $2,551
2021-03-31 $2,604
2020-12-31 $2,439
2020-09-30 $2,428
2020-06-30 $2,429
2020-03-31 $2,371
2019-12-31 $2,305
2019-09-30 $2,392
2019-06-30 $2,552
2019-03-31 $2,486
2018-12-31 $2,397
2018-09-30 $2,257
2018-06-30 $2,337
2018-03-31 $2,265
2017-12-31 $2,163
2017-09-30 $2,690
2017-06-30 $2,699
2017-03-31 $2,440
2016-12-31 $1,792
2016-09-30 $2,311
2016-06-30 $2,433
2016-03-31 $2,382
2015-12-31 $2,220
2015-09-30 $2,166
2015-06-30 $2,317
2015-03-31 $2,099
2014-12-31 $2,011
2014-09-30 $1,815
2014-06-30 $2,013
2014-03-31 $1,914
2013-12-31 $1,845
2013-09-30 $1,764
2013-06-30 $1,845
2013-03-31 $1,816
2012-12-31 $1,742
2012-09-30 $1,489
2012-06-30 $1,473
2012-03-31 $1,483
2011-12-31 $1,477
2011-09-30 $1,407
2011-06-30 $1,412
2011-03-31 $1,357
2010-12-31 $1,394
2010-09-30 $1,376
2010-06-30 $1,302
2010-03-31 $1,329
2009-12-31 $1,369
2009-09-30 $1,379
2009-06-30 $1,355
2009-03-31 $1,283
Sector Industry Market Cap Revenue
Medical Medical - Outpatient & Home Care $13.689B $12.140B
DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services. DaVita's Dialysis and related lab services business segment provides inpatient as well as outpatient dialysis services, routine laboratory testing for ESRD patients and management services to outpatient dialysis centers. The company's other ancillary services and strategic initiatives segment includes its international dialysis services, pharmacy services, infusion therapy services, disease management services, vascular access services, ESRD clinical research programs and physician services.
Stock Name Country Market Cap PE Ratio
Fresenius SE (FSNUY) Germany $21.379B 12.93
Quest Diagnostics (DGX) United States $17.308B 17.75
Encompass Health (EHC) United States $9.303B 22.88
Chemed (CHE) United States $8.694B 26.73
Elanco Animal Health (ELAN) United States $7.242B 16.28
Option Care Health (OPCH) United States $5.321B 26.14
RadNet (RDNT) United States $4.963B 117.74
Amedisys (AMED) United States $3.181B 22.75
Astrana Health (ASTH) United States $2.805B 39.69
LifeStance Health (LFST) United States $2.579B 0.00
Addus HomeCare (ADUS) United States $2.399B 29.12
U.S Physical Therapy (USPH) United States $1.274B 34.50
Pennant (PNTG) United States $1.057B 50.71
Aveanna Healthcare Holdings (AVAH) United States $1.022B 0.00
Atai Life Sciences (ATAI) Germany $0.208B 0.00
Daxor (DXR) United States $0.045B 0.00
ATI Physical Therapy (ATIP) United States $0.025B 0.00
MEDIROM Healthcare Technologies (MRM) Japan $0.019B 0.00
Psychemedics (PMD) United States $0.014B 0.00
Ontrak (OTRK) United States $0.010B 0.00
Novo Integrated Sciences (NVOS) United States $0.006B 0.00
IMAC Holdings (BACK) United States $0.002B 0.00